170. Occipital horn syndrome Clinical trials / Disease details

Clinical trials : 2 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 9 - Drug target pathways : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04977388 (ClinicalTrials.gov)	July 12, 2021	9/7/2021	NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome	Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial	Menkes Disease;Occipital Horn Syndrome	Drug: Droxidopa;Other: Placebo	Stephen G. Kaler, MD	NULL	Recruiting	18 Years	50 Years	All	6	Phase 1/Phase 2	United States
2	NCT00811785 (ClinicalTrials.gov)	February 27, 2009	18/12/2008	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency	Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency	Drug: Copper Histidine	Cyprium Therapeutics, Inc.	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH)	Completed	N/A	80 Years	All	93	Phase 3	United States